Skip to main content

Table 3 Clinical characteristics at baseline evaluation of the three study groups

From: Outpatient vs. home-based pulmonary rehabilitation in COPD: a randomized controlled trialRiabilitazione respiratoria ambulatoriale vs. domiciliare nella BPCO: studio randomizzato controllato

Variables At-home n = 33 Outpatient n = 23 Control n = 29
Dyspnea - MRC 0 8 (24.2) 6 (26.1) 8 (27.6)
Dyspnea - MRC 1 9 (27.3) 8 (34.8) 8 (27.6)
Dyspnea - MRC 2 10 (30.3) 5 (21.7) 10 (34.5)
Dyspnea - MRC 3 6 (18.2) 4 (17.4) 2 (6.9)
Dyspnea - MRC 4 0 (0) 0 (0) 1 (3.4)
Cough 31 (93.9) 20 (86.9) 26 (89.6)
Secretion 12 (36.4) 8 (34.8) 11 (37.9)
Wheezing 26 (78.8) 15 (65.2) 20 (69.0)
Post-bronchodilator spirometry  
FVC (L) 2.19 ± 0.71 2.51 ± 0.82 2.22 ± 0.55
FVC (%) 68.7 ± 30.2 79.1 ± 30.0 69.9 ± 28.0
FEV1 (L) 1.31 ± 0.76 1.32 ± 0.68 0.99 ± 0.46
FEV1 (%) 47.5 ± 23.3 51.5 ± 23.9 41.4 ± 18.4
FEV1/FVC (%) 69.1 ± 21.8 65.1 ± 24.5 59.2 ± 20.6
COPD stage  
GOLD I 4 (12.1) 2 (8.7) 2 (6.9)
GOLD II 8 (24.2) 10 (43.5) 6 (20.7)
GOLD III 11 (33.3) 5 (21.7) 13 (44.8)
GOLD IV 10 (30.3) 6 (26.1) 8 (27.6)
BODE 4 (0-7) 4 (0-8) 4 (1-9)
  1. Data expressed as absolute number and percentage (in parentheses) or mean ± standard deviation.
  2. Definition of abbreviatons: COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; GOLD, Global initiative for chronic obstructive lung disease; MRC, Medical Research Council.